Psoriasis is characterized by excessive growth and aberrant differentiation of keratinocytes and by dysregulation of immune cells. Topical vitamin D analogs and corticosteroids are commonly used for the treatment of mild-to-moderate plaque psoriasis. The effects of corticosteroids are predominantly anti-inflammatory and immunosuppressive, while those of vitamin D analogs have long been considered antiproliferative. Recent evidence suggests an independent role of vitamin D analogs and corticosteroids in cytokine modulation, an important factor in treatment efficacy. In vitro and in vivo studies show that the combination of a vitamin D analog and a corticosteroid produces effects on T-cell subsets that are involved in psoriatic skin inflammation. Based on the respective mechanisms of action of vitamin D analogs and corticosteroids, there is a biologic rationale for the enhanced clinical effect observed with the combination therapy. This article reviews current understanding of the pathogenesis of psoriasis and recent evidence for immunomodulatory mechanisms of vitamin D analogs and corticosteroids.
GottliebS.L., GilleaudeauP., JohnsonR.Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med.1995 May; 1(5): 442–7.
2.
EllisC.N., GorsulowskyD.C., HamiltonT.A.Cyclosporine improves psoriasis in a double-blind study. JAMA.1986 Dec 12; 256(22): 3110–6.
3.
BergboerJ.G., ZeeuwenP.L., SchalkwijkJ.Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol.2012 Oct; 132(10): 2320–1.
4.
van der VeldenH.M., PaschM.C., van ErpP.E.Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study. J Dermatolog Treat.2010 Jan; 21(1): 13–22.
5.
LovatoP., NorsgaardH., RopkeM.Key immune modulatory effects exerted by calcipotriol in combination with corticosteroid on human immune cells. Presented at the 21st European Academy of Dermatology and Venereology Congress; Prague, Czech Republic; 2012.
6.
VissersW.H., BerendsM., MuysL.The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol.2004 Feb; 13(2): 106–12.
FlatzL., ConradC.Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets and Therapy.2013 Feb; 3: 1–10.
10.
MartinD.A., TowneJ.E., KricorianG.The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol.2013 Jan; 133(1): 17–26.
11.
PietrzakA.T., ZalewskaA., ChodorowskaG.Cytokines and anticytokines in psoriasis. Clin Chim Acta.2008 Aug; 394(1-2): 7–21.
12.
BenhamH., NorrisP., GoodallJ.Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther.2013; 15(5): R136.
13.
ConradC., BoymanO., TonelG.Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med.2007 Jul; 13(7): 836–42.
14.
LowesM.A., KikuchiT., Fuentes-DuculanJ.Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol.2008 May; 128(5): 1207–11.
15.
PappK.A., LeonardiC., MenterA.Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med.2012 Mar 29; 366(13): 1181–9.
16.
LeonardiC., MathesonR., ZachariaeC.Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med.2012 Mar 29; 366(13): 1190–9.
17.
LeeE., TrepicchioW.L., OestreicherJ.L.Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med.2004 Jan 5; 199(1): 125–30.
18.
KinneyM.A., YentzerB.A., FeldmanS.IL-12/23 inhibitors and their potential benefits and risks for psoriasis patients. Psoriasis Forum.2010; 16(1): 16–20.
19.
LeonardiC.L., KimballA.B., PappK.A.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet.2008 May 17; 371(9625): 1665–74.
20.
PappK.A., LangleyR.G., LebwohlM.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet.2008 May 17; 371(9625): 1675–84.
21.
MenterA., KormanN.J., ElmetsC.A.Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol.2009 Apr; 60(4): 643–59.
22.
WeindlG., CastelloF., Schafer-KortingM.Evaluation of anti-inflammatory and atrophogenic effects of glucocorticoids on reconstructed human skin. Altern Lab Anim.2011 May; 39(2): 173–87.
23.
NorrisD.A.Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol.2005 Jul; 53(1 Suppl 1): S17–S25.
24.
LutherC., AdamopoulouE., StoeckleC.Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol.2009 Jul 15; 183(2): 841–8.
25.
YangY.H., AeberliD., DacumosA.Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J Immunol.2009 Jul 15; 183(2): 1435–45.
LeeS.W., TsouA.P., ChanH.Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc Natl Acad Sci U S A.1988 Feb; 85(4): 1204–8.
28.
KangS., YiS., GriffithsC.E.Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol.1998 Jan; 138(1): 77–83.
29.
MawlaM.A., AbulmajdY., SolimanM.Serum interleukin (IL)-17 in psoriasis. J Am Science.2013; 9(12): 229–32.
30.
StojadinovicO., LeeB., VouthounisC.Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation. J Biol Chem.2007 Feb 9; 282(6): 4021–34.
31.
OdaY., UchidaY., MoradianS.Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation. J Invest Dermatol.2009 Jun; 129(6): 1367–78.
32.
JensenA.M., LladoM.B., SkovL.Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol.1998 Dec; 139(6): 984–91.
33.
LuI., GilleaudeauP., McLaneJ.A.Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitriol. J Cutan Pathol.1996 Oct; 23(5): 419–30.
34.
PennaG., AdoriniL.1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol.2000 Mar 1; 164(5): 2405–11.
35.
PalmerM.T., LeeY.K., MaynardC.L.Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem.2011 Jan 14; 286(2): 997–1004.
36.
JefferyL.E., BurkeF., MuraM.1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol.2009 Nov 1; 183(9): 5458–67.
HegyiZ., ZwickerS., BureikD.Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 “alarmins” psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol.2012 May; 132(5): 1416–24.
39.
YamanakaK., DimitroffC.J., FuhlbriggeR.C.Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol.2008 Jan; 121(1): 148–57.
40.
van der AarA.M., SibiryakD.S., BakdashG.Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol.2011 Jun; 127(6): 1532–40.
41.
SegaertS., GarmynM., DegreefH., BouillonR.Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. J Invest Dermatol.1997 Jul; 109(1): 46–54.
42.
HinoR., KabashimaR., KawakamiC.Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate. J Eur Acad Dermatol Venereol.2011 Feb; 25(2): 242–4.
43.
GrossmanR.M., KruegerJ., YourishD.Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A.1989 Aug; 86(16): 6367–71.
44.
GoodmanW.A., LevineA.D., MassariJ.V.IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol.2009 Sep 1; 183(5): 3170–6.
45.
GniadeckiR.Stimulation versus inhibition of keratinocyte growth by 1,25-dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol.1996 Mar; 106(3): 510–6.
46.
KaoJ.S., FluhrJ.W., ManM.Q.Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol.2003 Mar; 120(3): 456–64.
47.
HongS.P., OhY., JungM.Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids. Br J Dermatol.2010 Jun; 162(6): 1251–60.
48.
NorsgaardH., DescarguesP., KurdykowskiS.Calcipotriol counteracts betamethasone-induced decrease in biomarkers related to skin atrophy. Presented at the 21st European Academy of Dermatology and Venereology Congress; Prague, Czech Republic; 2012.
49.
MenterA., GoldL.S., BukhaloM.Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol.2013 Jan; 12(1): 92–8.
50.
TraulsenJ., Hughes-FormellaB.J.The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology.2003; 207(2): 166–72.
51.
LugerT.A., CambazardF., LarsenF.G.A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology.2008; 217(4): 321–8.
52.
McCormackP.L.Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs.2011 Apr 16; 71(6): 709–30.
